Early studies on the cardioprotective effects of high doses (up to 20 g of eicosapentaenoic and docosahexaenoic acids, EPA and DHA, per day) of omega-3 fatty acids (FAs) suggested that these FAs primarily lowered triglyceride levels. These supraphysiological intake studies soon gave way to trials using lower and lower intakes of omega-3 FAs such that it is now clear that up to 45% lowering of serum triglyceride levels can be achieved with 3-4 g of EPA+DHA. This is an intake that can hardly be achieved by dietary means; direct supplementation is required. This is a public health challenge since implementing wide-scale supplementation programmes would be difficult.
A review of the studies on the effects of small doses (<2g.day 1 ) of omega-3 FAs on serum triglyceride levels suggests that serum triglyceride levels decreased in every study (compared with control or placebo treatment). The decreases were often not statistically significant, but this is to be expected with small doses given for short timeperiods. Four of the five studies that examined postprandial lipids (PPL) reported significant reductions in this parameter even when fasting levels were not altered. This suggests that chronic intake of small amounts of omega-3 FAs may reduce overall (day-long) triglyceride-rich lipoprotein levels which could have long-term implications for the reduction of CHD risk.
Whilst the cardioprotective effects of omega-3 FAs are becoming well documented, the question of whether such beneficial effects of omega-3 FAs are at least partially mediated by changes in serum levels of triglyceride-rich lipoproteins or their remnants remains open. Further studies to examine the effects of this low level of intake are clearly needed to determine the relative contribution of hypolipidaemic mechanisms versus those involving diminished platelet function, altered adhesion molecule
Introduction
One of the earliest proposed mechanisms for the cardioprotective effects of omega-3 fatty acids (FAs) observed in Greenland Eskimos was lipid lowering [1] . Although early studies suggested that these FAs (eicosapentaenoic and docosahexaenoic acids, EPA and DHA) lowered serum cholesterol levels, later work revealed that the primary lipid fraction impacted was triglycerides. This has now been confirmed many times over [2, 3] . Our early work with omega-3 FAs involved studies with salmon oil, and we examined the hypolipidaemic effects of more than 20 g of EPA+DHA per day [4] . These supraphysiological intake studies soon gave way to trials using lower and lower intakes of omega-3 FAs such that it is now clear that up to 45% lowering of serum triglyceride levels can be achieved with 3-4 g of EPA+DHA [5] . This intake can be achieved with four capsules of Omacor (Pronova Biocare, Oslo) ESAPENT or SEACOR
. Although this dose is now known to be effective in lowering triglyceride levels, its impact on clinical coronary heart disease end-points is not well documented. In addition, this is an intake that can hardly be achieved by dietary means; direct supplementation is required. This is a public health challenge since implementing wide-scale supplementation programmes would be difficult. If lower, nutritionally achievable intakes of omega-3 FAs could be shown to have clinical benefit, incorporating them into traditional foods might feasibly impact CHD incidence populationwide.
With the publication of the DART study [6] and more recently the GISSI--Prevenzione Study [7] , it is becoming clear that quite small intakes of omega-3 FAs (700-1000 mg/day) can significantly impact CHD risk. These long-term, secondary prevention trials reported 29% and 20% reductions in total mortality, respectively, in patients consuming 700-850 mg of EPA+DHA per day for 2-3·5 years. Thus, the cardioprotective effects of omega-3 FAs are becoming well documented, although the mechanism remains unclear. Can changes in serum lipid levels explain this level of protection, or must we look elsewhere for an explanation for the beneficial effects of omega-3 FAs in these patients? This review will summarize current data regarding the effects of small doses (<2 g . day) of omega-3 FAs on serum triglyceride levels, and will speculate on how this may play a role in the cardioprotection observed.
Impact of low intakes of omega-3 FAs on serum triglyceride levels
Relatively few investigators have examined the effects of low (<2 g) EPA+DHA on serum lipid profiles, presumably because there was little expectation that any benefit would be detectable. Nevertheless, there is growing interest in quantifying not only the effects on fasting lipids but those on postprandial lipids as well. Table 1 summarizes many of the studies which provided this low level of omega-3 FAs. They can be separated generally into fish-based, food-based and capsule-based studies. As seen in Table 1 , serum triglyceride levels decreased in every study (compared with control or placebo treatment). The decreases were often not statistically significant, but this is to be expected with small doses given for short time-periods. It is interesting that four of the five studies that examined postprandial lipids (PPL) reported significant reductions in this parameter even when fasting levels were not altered. This suggests that chronic intake of small amounts of omega-3 FAs may reduce overall (daylong) triglyceride-rich lipoprotein levels, which could have long-term implications for the reduction of CHD risk [29] [30] [31] .
In conclusion, the question of whether the beneficial, cardioprotective effects of omega-3 FAs is at least partially mediated by changes in serum levels of triglyceride-rich lipoproteins or their remnants remains open. Further studies examining the effects of this low level of intake are clearly needed to determine the relative contribution of hypolipidaemic mechanisms versus those involving diminished platelet function, altered adhesion molecule expression, improvements in endothelial function and antiarrhythmic or hypotensive effects. [8] 1996 Fish 15 1·05 15% (PPL?)* Schaefer [9] 1992 Fish 24 1·8 7% (PPL?)* De Oliviera e Silva [10] 1996 Shrimp 3 0·81 19%* Fahrer [11] 1991 Fish 8 1·75 19%* Jacques [12] 1992 Fish 8 0·45 8% Gerhard [13] 1991 Fish 2·51 · 95 1% Brown [14] 1990
Fish 6 0·7 7% A r gren [15] 1988 Fish 15 0·8 16%* Fehily [16] 1983 Fish 12 0·7 7%* Brown [17] 1991 Capsules 6 1·5 25% (PPL?)* Oosthuizen [18] 1994 Capsules 6 1·6 17% Valdini [19] 1990
Capsules 12 1·8 16% Gans [20] 1990
Capsules 16 1·8 33%* Beil [21] 1991 Capsules 6 1·6 20% Radack [22] 1990
Capsules 20 1·1 10% Roche [23] 1996
Capsules 16 0·8 21% (PPL?)* Demke [24] 1988 Capsules 4 1·5 24% Schindler [25] 1998 Capsules 2 1·1 (0·18 to 1·1 g . day 1 )
16-34%* (depending on phenotype) Saldeen [26] 1998 Bread 4 0·3 17%* Lovegrove [27] 1997 Multifoods 3 1·4 4% (PPL?) Sørensen [28] 1998
Margarine 23 0·9 12%* *=statistically significant. PPL=postprandial lipemia; ?=lower on omega-3 FAs.
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